VTv Therapeutics
VTv Therapeutics, a pharmaceutical company, focusses on the discovery and development of human therapeutics to fill unmet medical needs.
Launch date
Employees
Market cap
AUD53.6m
Enterprise valuation
(AUD16m) (Public information from Sep 2024)
Share price
$14.93 VTVT
High Point North Carolina (HQ)
Financials
Estimates*
| USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | <1m | 12.4m | 2.8m | 6.4m | 4.0m | 2.0m | - |
| % growth | - | 4173 % | (78 %) | 132 % | (38 %) | (50 %) | - |
| EBITDA | (50.6m) | (20.1m) | (20.0m) | (12.1m) | (17.6m) | (24.9m) | (25.9m) |
| % EBITDA margin | (17374 %) | (162 %) | (724 %) | (189 %) | (440 %) | (1232 %) | - |
| Profit | (16.1m) | (7.9m) | (13.0m) | (8.5m) | (13.0m) | (19.2m) | (20.2m) |
| % profit margin | (5548 %) | (64 %) | (472 %) | (133 %) | (324 %) | (950 %) | - |
| EV / revenue | 227.1x | 5.4x | 27.0x | 14.5x | 13.5x | 21.1x | - |
| EV / EBITDA | -1.3x | -3.3x | -3.7x | -7.7x | -3.1x | -1.7x | -0.6x |
| R&D budget | 39.6m | 23.0m | 15.1m | 11.0m | 13.3m | 12.4m | 13.6m |
| R&D % of revenue | 13622 % | 185 % | 547 % | 172 % | 333 % | 612 % | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | N/A | IPO | |
| N/A | $2.0m | Post IPO Equity | |
* | N/A | $25.0m | Post IPO Equity |
* | $51.0m | Private Placement VC | |
| Total Funding | AUD78.8m | ||
Related Content
Recent News about VTv Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.